Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

LMNA knock-down affects differentiation and progression of human neuroblastoma cells.

Maresca G, Natoli M, Nardella M, Arisi I, Trisciuoglio D, Desideri M, Brandi R, D'Aguanno S, Nicotra MR, D'Onofrio M, Urbani A, Natali PG, Del Bufalo D, Felsani A, D'Agnano I.

PLoS One. 2012;7(9):e45513. doi: 10.1371/journal.pone.0045513. Epub 2012 Sep 26.

2.

Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors.

Salvatori L, Caporuscio F, Verdina A, Starace G, Crispi S, Nicotra MR, Russo A, Calogero RA, Morgante E, Natali PG, Russo MA, Petrangeli E.

PLoS One. 2012;7(2):e31467. doi: 10.1371/journal.pone.0031467. Epub 2012 Feb 6.

3.

Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.

Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P.

Neoplasia. 2011 Sep;13(9):822-30.

4.

Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.

Clin Cancer Res. 2011 Apr 15;17(8):2350-60. doi: 10.1158/1078-0432.CCR-10-2325. Epub 2011 Jan 10.

5.

CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.

Taghizadeh R, Noh M, Huh YH, Ciusani E, Sigalotti L, Maio M, Arosio B, Nicotra MR, Natali P, Sherley JL, La Porta CA.

PLoS One. 2010 Dec 22;5(12):e15183. doi: 10.1371/journal.pone.0015183.

6.

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

PLoS One. 2010 Jun 21;5(6):e11241. doi: 10.1371/journal.pone.0011241.

7.

In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor.

Kurzik-Dumke U, Hörner M, Nicotra MR, Koslowski M, Natali PG.

J Transl Med. 2010 Jun 17;8:58. doi: 10.1186/1479-5876-8-58.

8.

NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.

Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D.

Cancer Res. 2010 Feb 1;70(3):916-24. doi: 10.1158/0008-5472.CAN-09-2582. Epub 2010 Jan 26. Erratum in: Cancer Res. 2010 Apr 1;70(7):2995.

9.

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

Spinella F, Garrafa E, Di Castro V, Rosanò L, Nicotra MR, Caruso A, Natali PG, Bagnato A.

Cancer Res. 2009 Mar 15;69(6):2669-76. doi: 10.1158/0008-5472.CAN-08-1879. Epub 2009 Mar 10.

10.

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.

Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11. doi: 10.1073/pnas.0807158106. Epub 2009 Feb 6.

11.

Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues.

Fruci D, Giacomini P, Nicotra MR, Forloni M, Fraioli R, Saveanu L, van Endert P, Natali PG.

J Cell Physiol. 2008 Sep;216(3):742-9. doi: 10.1002/jcp.21454.

PMID:
18393273
12.

Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor.

Kurzik-Dumke U, Hörner M, Czaja J, Nicotra MR, Simiantonaki N, Koslowski M, Natali PG.

Int J Mol Med. 2008 Jan;21(1):19-31.

PMID:
18097612
13.
14.

Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.

Rosanò L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A.

Cancer Res. 2007 Jul 1;67(13):6351-9.

15.

Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.

Di Modugno F, DeMonte L, Balsamo M, Bronzi G, Nicotra MR, Alessio M, Jager E, Condeelis JS, Santoni A, Natali PG, Nisticò P.

Cancer Res. 2007 Mar 15;67(6):2657-65.

16.

Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.

Spinella F, Rosanò L, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A.

Cancer Res. 2007 Feb 15;67(4):1725-34.

17.

Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.

Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, Nicotra MR, Natali PG, Bagnato A.

Mol Cancer Ther. 2006 Jun;5(6):1483-92.

18.

Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.

Uccini S, Colarossi C, Scarpino S, Boldrini R, Natali PG, Nicotra MR, Perla FM, Mannarino O, Altavista P, Boglino C, Cappelli CA, Cozzi D, Donfrancesco A, Kokai G, Losty PD, McDowell HP, Dominici C.

Br J Cancer. 2006 Jul 3;95(1):49-55. Epub 2006 Jun 6.

19.

Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.

Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A.

Exp Biol Med (Maywood). 2006 Jun;231(6):1128-31.

PMID:
16741062
20.

Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.

Rosanò L, Spinella F, Di Castro V, Dedhar S, Nicotra MR, Natali PG, Bagnato A.

Mol Cancer Ther. 2006 Apr;5(4):833-42.

21.

cDNA-array profiling of melanomas and paired melanocyte cultures.

Mischiati C, Natali PG, Sereni A, Sibilio L, Giorda E, Cappellacci S, Nicotra MR, Mariani G, Di Filippo F, Catricalà C, Gambari R, Grammatico P, Giacomini P.

J Cell Physiol. 2006 Jun;207(3):697-705.

PMID:
16523488
22.

Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.

Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, Bagnato A.

Cancer Res. 2005 Dec 15;65(24):11649-57.

23.

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.

Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M.

J Cell Physiol. 2006 Apr;207(1):58-66.

PMID:
16252259
24.

Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.

Uccini S, Mannarino O, McDowell HP, Pauser U, Vitali R, Natali PG, Altavista P, Andreano T, Coco S, Boldrini R, Bosco S, Clerico A, Cozzi D, Donfrancesco A, Inserra A, Kokai G, Losty PD, Nicotra MR, Raschellà G, Tonini GP, Dominici C.

Clin Cancer Res. 2005 Jan 1;11(1):380-9.

25.

Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.

Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

Clin Cancer Res. 2004 Jul 15;10(14):4670-9.

26.

Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.

Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, Botti C, Nicotra MR, Mottolese M, Natali PG, Santoni A, Jager E, Nisticò P.

Int J Cancer. 2004 May 10;109(6):909-18.

27.

Mite antigens enhance ICAM-1 and induce VCAM-1 expression on human umbilical vein endothelium.

Mastrandrea F, Nicotra MR, De Vita L, Coradduzza G, Minardi A, Scarcia G, Manelli M, Cadario G, Parmiani S, Natali PG.

Allergol Immunopathol (Madr). 2003 Sep-Oct;31(5):259-64.

PMID:
14572414
28.

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.

Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M.

Oncogene. 2003 Sep 29;22(42):6557-63. Review.

PMID:
14528280
29.

Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells.

Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

J Biol Chem. 2003 Oct 17;278(42):41294-301. Epub 2003 Aug 7.

30.

Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.

Rosanò L, Spinella F, Di Castro V, Nicotra MR, Albini A, Natali PG, Bagnato A.

Am J Pathol. 2003 Aug;163(2):753-62.

31.

c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.

Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschellà G, Dominici C.

Int J Cancer. 2003 Aug 20;106(2):147-52.

32.

Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.

Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A.

Cancer Res. 2003 May 15;63(10):2447-53.

33.

Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.

Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, Venuti A.

Cancer Res. 2002 Nov 15;62(22):6381-4.

34.

ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.

Salani D, Rosanò L, Di Castro V, Spinella F, Venuti A, Padley RJ, Nicotra MR, Natali PG, Bagnato A.

Clin Sci (Lond). 2002 Aug;103 Suppl 48:318S-321S.

PMID:
12193113
35.

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.

Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G.

Gynecol Oncol. 2002 May;85(2):305-10.

PMID:
11972392
36.

Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.

Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M.

J Cell Physiol. 2001 Jul;188(1):1-7. Review.

PMID:
11382917
37.

Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells.

Bagnato A, Rosanò L, Di Castro V, Albini A, Salani D, Varmi M, Nicotra MR, Natali PG.

Am J Pathol. 2001 Mar;158(3):841-7.

38.

Role of endothelin-1 in neovascularization of ovarian carcinoma.

Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, Natali PG, Bagnato A.

Am J Pathol. 2000 Nov;157(5):1537-47.

39.

Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment.

Frumento G, Franchello S, Palmisano GL, Nicotra MR, Giacomini P, Loke YW, Geraghty DE, Maio M, Manzo C, Natali PG, Ferrara GB.

Tissue Antigens. 2000 Jul;56(1):30-7.

PMID:
10958353
40.

Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.

Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M.

Clin Cancer Res. 2000 May;6(5):2037-43.

41.

Hemopoietic progenitor cells in atopic dermatitis skin lesions.

Mastrandrea F, Cadario G, Nicotra MR, Natali PG.

J Investig Allergol Clin Immunol. 1999 Nov-Dec;9(6):386-91.

PMID:
10664934
42.

Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines.

Giacomini P, Giorda E, Fraioli R, Nicotra MR, Vitale N, Setini A, Delfino L, Morabito A, Benevolo M, Venturo I, Mottolese M, Ferrara GB, Natali PG.

Cancer Res. 1999 Jun 1;59(11):2657-67.

43.

Expression of T-lineage early developmental markers by cells establishing atopic dermatitis skin infiltrates.

Mastrandrea F, Cadario G, Bedello PG, Nicotra MR, Natali PG.

J Investig Allergol Clin Immunol. 1998 Nov-Dec;8(6):359-64.

PMID:
10028483
44.

Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth.

Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG.

Cancer Res. 1999 Feb 1;59(3):720-7.

46.

Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas.

Pietsch T, Nicotra MR, Fraioli R, Wolf HK, Mottolese M, Natali PG.

Int J Cancer. 1998 Jan 19;75(2):171-5.

47.

HLA-C heavy chains free of beta2-microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-gamma responsiveness.

Giacomini P, Beretta A, Nicotra MR, Ciccarelli G, Martayan A, Cerboni C, Lopalco L, Bini D, Delfino L, Ferrara GB, Siccardi AG, Natali PG.

Tissue Antigens. 1997 Dec;50(6):555-66.

PMID:
9458108
48.

Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.

Nicotra MR, Nisticò P, Mangoni A, Di Filippo F, Marincola FM, Natali PG.

J Immunother. 1997 Nov;20(6):466-9.

PMID:
9409452
49.

Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.

Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M, Ferrone S.

Cancer Res. 1997 Apr 15;57(8):1554-60.

50.

Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells.

Fonsatti E, Altomonte M, Coral S, Cattarossi I, Nicotra MR, Gasparollo A, Natali PG, Maio M.

Br J Cancer. 1997;76(10):1255-61.

Supplemental Content

Loading ...
Support Center